Haemonetics/HAE

$83.62

2.92%
-
1D1W1MYTD1YMAX

About Haemonetics

Haemonetics Corporation is a global healthcare company. The Company provides a suite of medical products and solutions for customers to help them improve patient care and reduce the cost of healthcare. Its technology addresses three medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. Its segments include Plasma, Blood Center, and Hospital. Its Plasma segment offers automated plasma collection systems, donor management software, and supporting software solutions that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to collect and separate blood components for transfusions. Its Hospital segment provides patient care and has four product lines: hemostasis management, vascular closure, cell salvage, and transfusion management. Its portfolio also includes fiber optic sensor technology in the interventional cardiology market.

Ticker

HAE

Sector

Healthcare

Trading on

NYSE

Industry

Medical Equipment & Supplies

CEO

Christopher Simon

Employees

3,034

Headquarters

Boston, United States

Haemonetics Metrics

BasicAdvanced
$4.13B
Market cap
32.87
P/E ratio
$2.47
EPS
0.37
Beta
-
Dividend rate
$4.13B
0.37378
$95.26
$70.74
486.41K
2.923
1.761
90.833
92.29
31.705
26.49%
6.21%
14.72%
7.05%
32.873
3.248
4.374
32.045
12.48%
32.77%
5.74%
14.97%

What the Analysts think about Haemonetics

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
26.25% upside
High $120.00
Low $88.00
$83.62
Current price
$105.57
Average price target

Haemonetics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
9.28% profit margin
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$336.2M
5.69%
Net income
$31.2M
25.3%
Profit margin
9.28%
18.67%

Haemonetics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 10.47%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$0.77
$1.05
$0.99
$1.04
-
Expected
$0.70
$0.73
$0.89
$0.94
$0.89
Surprise
9.24%
43.74%
11.47%
10.47%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Haemonetics stock?

Haemonetics (HAE) has a market cap of $4.13B as of April 23, 2024.

What is the P/E ratio for Haemonetics stock?

The price to earnings (P/E) ratio for Haemonetics (HAE) stock is 32.87 as of April 23, 2024.

Does Haemonetics stock pay dividends?

No, Haemonetics (HAE) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Haemonetics dividend payment date?

Haemonetics (HAE) stock does not pay dividends to its shareholders.

What is the beta indicator for Haemonetics?

Haemonetics (HAE) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Haemonetics stock price target?

The target price for Haemonetics (HAE) stock is $105.57, which is 26.25% above the current price of $83.62. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Haemonetics stock

Buy or sell Haemonetics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing